Regorafenib Combination Therapy in Advanced Hepatocellular Carcinoma: With or without Transarterial Chemoembolization
Oncology · 27.11.2024 · 103 (9) · 780-793
DOI: 10.1159/000542775 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, online erschienen am 27.11.2024. Verfasst von Lei Cao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu,…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Pyridines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Introduction
The effectiveness and tolerability of triple therapy, which combines regorafenib, a programmed death 1 (PD-1) inhibitor, and transarterial chemoembolization (TACE), were compared to dual therapy consisting of regorafenib and a PD-1 inhibitor in patients with advanced hepatocellular carcinoma (HCC).
Methods
A retrospective analysis was conducted on patients with advanced HCC who underwent second-line therapy from March 2019 to June 2022 at multiple centers. Patients were stratified into two groups: dual therapy (comprising regorafenib and a PD-1 inhibitor) and triple therapy (consisting of regorafenib, a PD-1 inhibitor, and TACE). Propensity score matching (PSM) was used to control for potential confounding variables.
Results
After PSM, 112 eligible patients were included, with 56 in the triple therapy group and 56 in the dual therapy group. Median overall survival (OS) was significantly longer in the triple therapy group (15.4 vs. 8.9 months, p < 0.001), as was median progression-free survival (6.8 vs. 3.3 months, p < 0.001). The objective response rate (37.5% vs. 5.4%, p < 0.001) and disease control rate (73.2% vs. 44.6%, p = 0.002) were significantly higher in the triple therapy group compared to the dual therapy group. The incidence and severity of adverse events were similar between the two groups.
Conclusion
Triple therapy demonstrated superior survival benefits compared to dual therapy in patients with advanced HCC. Additionally, the safety profiles of the two treatment regimens were comparable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, leicao.sc@gmail.com.
- Department of hepatobiliary surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Department of vascular surgery, Ziyang City People's Hospital, Ziyang, China.
- Department of Radiology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Zitieren
APA
Cao, L., Lu, X., Chen, H., Yu, X., Li, J., Peng, Y., Gu, L., Feng, J., Xie, P., Liu, Y., & Liu, Y. (2024). Regorafenib Combination Therapy in Advanced Hepatocellular Carcinoma: With or without Transarterial Chemoembolization. Oncology, 103(9), 780-793. https://doi.org/10.1159/000542775
Vancouver
Cao L, Lu X, Chen H, Yu X, Li J, Peng Y, et al. Regorafenib Combination Therapy in Advanced Hepatocellular Carcinoma: With or without Transarterial Chemoembolization. Oncology. 2024;103(9):780-793. doi:10.1159/000542775
BibTeX
@article{Cao2024,
author = {Cao, Lei and Lu, Xiangyu and Chen, Haoqing and Yu, Xiang and Li, Jinze and Peng, Yi and Gu, Lu and Feng, Ji and Xie, Ping and Liu, Yaben and Liu, Yaben},
title = {Regorafenib Combination Therapy in Advanced Hepatocellular Carcinoma: With or without Transarterial Chemoembolization},
journal = {Oncology},
year = {2024},
volume = {103},
number = {9},
pages = {780--793},
doi = {10.1159/000542775}
}
EUVIMED